• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cytogenetic analysis in patients with primary myelodysplastic syndromes in leukaemic transformation. A report on 94 cases. Groupe Français de Cytogénétique Hématologique (GFCH).

出版信息

Hematol Cell Ther. 1996 Apr;38(2):177-81. doi: 10.1007/s00282-996-0177-7.

DOI:10.1007/s00282-996-0177-7
PMID:8931999
Abstract

A series of 94 patients presenting primary refractory anaemia with excess of blasts in transformation or acute myeloid leukaemia occurring after a myelodysplastic stage was submitted to retrospective cytogenetic analysis by the Groupe Français de Cytogénétique Hématologique. The aim of this collaborative study was to analyze the patterns of chromosome abnormalities appearing in primary myelodysplastic syndromes (MDS) in leukaemic transformation. As previously described in the literature, the most common chromosome aberrations involved del(5q), -7, +8, 17, 11, 12p and del(20q), while abnormalities of chromosome 17p were more frequently detected during the leukaemic transformation of MDS. The translocations t(2;3) (p22-23;q26-28) and whole arm t(17;18) were confirmed to be nonrandom events in these myeloid disorders.

摘要

相似文献

1
Cytogenetic analysis in patients with primary myelodysplastic syndromes in leukaemic transformation. A report on 94 cases. Groupe Français de Cytogénétique Hématologique (GFCH).
Hematol Cell Ther. 1996 Apr;38(2):177-81. doi: 10.1007/s00282-996-0177-7.
2
A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).一种新的复发性易位,t(5;11)(q35;p15.5),与儿童急性髓系白血病中的5号染色体长臂缺失(del(5q))相关。英国癌症细胞遗传学组(UKCCG)。
Blood. 1999 Jul 15;94(2):773-80.
3
Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?110例伴有5号染色体异常的造血系统疾病的荧光原位杂交分析:原发性与治疗相关的骨髓增生异常综合征-急性髓系白血病真的有区别吗?
Cancer Genet Cytogenet. 2007 Jul 1;176(1):1-21. doi: 10.1016/j.cancergencyto.2007.01.013.
4
Acute leukemia treated with intensive chemotherapy in patients with a history of previous chemo- and/or radiotherapy: prognostic significance of karyotype and preceding myelodysplastic syndrome. Groupe Francais de Cytogénétique Hématologique (GFCH).曾接受过化疗和/或放疗的患者接受强化化疗治疗急性白血病:核型及先前骨髓增生异常综合征的预后意义。法国血液细胞遗传学小组(GFCH)
Leukemia. 1994 Jan;8(1):87-91.
5
Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.老年患者骨髓增生异常综合征与急性髓系白血病之间的细胞遗传学类比
Leukemia. 2000 Apr;14(4):636-41. doi: 10.1038/sj.leu.2401711.
6
Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).骨髓增生异常肿瘤(骨髓增生异常综合征,MDS)的细胞遗传学管理:法国血液细胞遗传学组(GFCH)的指南。
Curr Res Transl Med. 2023 Oct-Dec;71(4):103409. doi: 10.1016/j.retram.2023.103409. Epub 2023 Sep 17.
7
Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome. A multicenter study of 55 patients. Groupe Français de Cytogénétique Hématologique.
Cancer Genet Cytogenet. 1988 Jun;32(2):157-68. doi: 10.1016/0165-4608(88)90278-6.
8
Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes.112例未经治疗的骨髓增生异常综合征的细胞遗传学研究。
Cancer Genet Cytogenet. 1992 Nov;64(1):12-20. doi: 10.1016/0165-4608(92)90315-y.
9
AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.骨髓增生异常综合征患者中与急性髓系白血病相关的细胞遗传学异常(inv(16)、del(16)、t(8;21))
Hematol Pathol. 1992;6(1):43-8.
10
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.接受来那度胺治疗后未能获得持续红细胞或细胞遗传学缓解的 del(5q) MDS 患者,其克隆进化和 AML 进展的风险增加。
Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.